Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029559

Enrollment

Unknown

Registered

2020-02-04

Start date

2020-01-31

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

experimental group 2:Hydroxychloroquine 0.2 oral 2/ day

Placebo control group:Starch pill oral 2/ day

experimental group 1:Hydroxychloroquine 0.1 oral 2/ day

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.

Design outcomes

Primary

Measure	Time frame
The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;	—

Countries

China

Contacts

Public ContactZhang Zhan

Renmin Hospital of Wuhan University

doctorzhang2003@163.com+86 18962567610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026